Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01970943|
Recruitment Status : Unknown
Verified January 2015 by David Borsook, Mclean Hospital.
Recruitment status was: Active, not recruiting
First Posted : October 28, 2013
Last Update Posted : January 30, 2015
|Condition or disease||Intervention/treatment||Phase|
|Migraine Healthy||Other: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||28 participants|
|Intervention Model:||Crossover Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Molecular and Functional PET-fMRI Measures of Analgesia in Migraine|
|Study Start Date :||March 2013|
|Primary Completion Date :||April 2014|
No Intervention: No Intervention
PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.
Placebo Comparator: Saline Injection (Placebo)
PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.
Placebo will be compared to No Intervention.
- VAS Pain rating [ Time Frame: 1 day ]This study will investigate how placebo may reduce experimental pain induced by contact heat.
- fMRI BOLD signal [ Time Frame: 1 day ]Functional Magnetic Resonance Imaging Blood Oxygenation Level Dependent Signal will be obtained.
- PET Diprenorphine [ Time Frame: 1 day ]Positron Emission Tomography with C11 diprenorphine will be used to measure opioid receptors
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01970943
|United States, Massachusetts|
|Athinoula A. Martinos. Center for Biomedical Imaging|
|Charlestown, Massachusetts, United States, 02129|
|Principal Investigator:||David Borsook, MD, Ph.D||Boston Children’s Hospital|